Group 1 - The company is expanding its cross-border e-commerce operations, focusing on daily eye health products [2] - Malaysia has already initiated the process for selling these products, while other Southeast Asian countries are in preparation [2] - The main products include orthokeratology lenses, scleral lenses, and care products, which are classified as medical devices requiring local registration before sales [2]

（文章来源：证券日报） 证券日报网讯 7月31日晚间，欧普康视发布公告称，公司于2025年7月3日召开第四届董事会第十六次会 议和第四届监事会第十六次会议、于2025年7月22日召开2025年第一次临时股东大会，分别审议通过了 《关于变更部分募集资金用途并用于收购宿迁市尚悦启程医院管理有限公司75%股权的议案》，同意公 司使用33，390.00万元收购宿迁市尚悦启程医院管理有限公司75%股权，其中使用募集资金23，373.00 万元，自有资金10，017.00万元，同时提请股东大会授权公司董事长或其指定的授权对象办理与上述项 目变更和实施有关的所有事项，以及开立募集资金专户、签署募集资金多方监管协议等相关事宜。近 日，公司在兴业银行股份有限公司合肥分行开立募集资金专项账户，且公司、国元证券股份有限公司及 兴业银行股份有限公司合肥分行签署了《募集资金三方监管协议》。 ...

欧普康视科技股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日召开 第四届董事会第十六次会议和第四届监事会第十六次会议、于 2025 年 7 月 22 日 召开 2025 年第一次临时股东大会，分别审议通过了《关于变更部分募集资金用 途并用于收购宿迁市尚悦启程医院管理有限公司75%股权的议案》，同意公司使 用 33,390.00 万元收购宿迁市尚悦启程医院管理有限公司 75%股权，其中使用募 集资金 23,373.00 万元，自有资金 10,017.00 万元，同时提请股东大会授权公 司董事长或其指定的授权对象办理与上述项目变更和实施有关的所有事项，以 及开立募集资金专户、签署募集资金多方监管协议等相关事宜。具体内容详见 公司于 2025 年 7 月 5 日在巨潮资讯网（http://www.cninfo.com.cn）披露的 《关于变更部分募集资金用途并用于收购宿迁市尚悦启程医院管理有限公司75% 股权的公告》。 近日，公司、国元证券股份有限公司及兴业银行股份有限公司合肥分行签 署了《募集资金三方监管协议》，具体情况如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意欧普康视科技 ...

Group 1 - The stock price of Oupankangshi on July 30 was 18.12 yuan, a decrease of 0.08 yuan, representing a decline of 0.44% from the previous trading day [1] - The trading volume on that day was 258,927 hands, with a total transaction amount of 472 million yuan [1] - As of July 18, 2025, the total number of shareholders for Oupankangshi was 62,918 [1] Group 2 - The company's main business involves the research, development, production, and sales of ophthalmic medical devices [1] - Key products include orthokeratology lenses and rigid gas permeable contact lenses [1] - On July 30, the net inflow of main funds was 5.5334 million yuan [1]

证券日报网讯欧普康视（300595）7月30日在互动平台回答投资者提问时表示，截至2025年7月18日，公 司股东总人数为62918户。 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Core Viewpoint - The medical device industry experienced a slight decline of 0.02% on July 23, with a total capital inflow of 23.87 million [1] Group 1: Market Performance - A total of 49 stocks in the sector rose, while 71 stocks fell [1] - The top ten decliners included: - JinHao Medical (-6.2%) - WeiSi Medical (-6.18%) - BeiYiKang (-5.91%) - Rejing Biology (-5.1%) - AiPeng Medical (-3.78%) - DiRui Medical (-3.55%) - YingKe Medical (-2.78%) - AiWei Technology (-2.58%) - YiRui Technology (-2.46%) - KangTuo Medical (-2.35%) [1] Group 2: Capital Flow - The net capital outflow for the top decliners included: - JinHao Medical: -15.52 million - WeiSi Medical: -13.50 million - BeiYiKang: -9.36 million - Rejing Biology: -14.75 million - AiPeng Medical: -15.57 million [1] Group 3: Top Gainers - The top gainers in the sector included: - OuPuKangShi (14.13%) - TouJing Life (5.7%) - KangZhong Medical (5.07%) - TianYi Medical (4.97%) - AoTai Biology (3.52%) [1]

Market Overview - As of 10:29 AM today, the Shanghai Composite Index stands at 3592.77 points, above the annual line, with a change of 0.30% [1] - The total trading volume of A-shares today is 857.68 billion yuan [1] Stocks Breaking Annual Line - A total of 27 A-shares have surpassed the annual line today, with notable stocks including: - Opcon Vision (300595) with a deviation rate of 9.58% - Mars (300894) with a deviation rate of 6.80% - Xianju Pharmaceutical (002332) with a deviation rate of 3.03% [1] Deviation Rate Rankings - The following stocks have the highest deviation rates from the annual line: - Opcon Vision: Today's increase of 12.38%, turnover rate of 3.83%, annual line at 16.41 yuan, latest price at 17.98 yuan [1] - Mars: Today's increase of 8.18%, turnover rate of 8.48%, annual line at 13.62 yuan, latest price at 14.55 yuan [1] - Xianju Pharmaceutical: Today's increase of 5.12%, turnover rate of 5.68%, annual line at 10.36 yuan, latest price at 10.67 yuan [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the annual line include: - Beiqi Blue Valley (600733) with a deviation rate of 0.03% - Qianhe Flavor (603027) with a deviation rate of 0.05% - Luyang Energy (002088) with a deviation rate of 0.15% [2]

Core Viewpoint - The medical device sector is experiencing a rally, driven by the active innovation drug concept, with significant gains in stock prices for companies like Opcon Vision, which hit a 20% limit up [1] Group 1: Market Performance - Opcon Vision's stock reached a 20% limit up, indicating strong investor interest and confidence in the company [1] - Other companies in the sector, such as Maipu Medical, saw stock increases of over 10%, reflecting a broader positive trend in the medical device market [1] Group 2: Industry Insights - According to a report from Guotai Junan, domestic equipment monthly bidding data shows a continuous recovery, suggesting improving market conditions [1] - As inventory pressures ease, equipment companies are expected to see a quarter-on-quarter performance recovery in Q3, indicating a potential turnaround in the sector's financial health [1]

证券代码：300595 证券简称：欧普康视 公告编号：2025- 060 欧普康视科技股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会召开期间无否决提案的情况； 2、本次股东大会未出现涉及变更以往股东大会已通过决议的情况。 一、会议召开和出席情况 1、会议召开时间： 现场会议时间：2025 年 7 月 22 日 14:45 网络投票时间：通过深圳证券交易所交易系统网络投票时间为 7 月 22 日 9:15-9:25，9:30-11:30 和 13:00-15:00；深圳证券交易所互联网投票系统投票 时间为 7 月 22 日 9:15 至 15:00。 2、会议召开地点：合肥市高新技术开发区望江西路 4899 号 2 号楼二楼会议 室。 3、会议召开方式：现场投票与网络投票相结合的方式。 4、会议召集人：公司第四届董事会。 5、会议主持人：公司董事长陶悦群先生。 6、本次股东大会召集、召开与表决程序符合《公司法》《上市公司股东会 规则》等法律、行政法规、部门规章、规范性文件和《公司 ...